• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Advaxis, Inc.

    4/1/24 4:31:36 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care
    Get the next $ADXS alert in real time by email
    NT 10-K 1 nt10k.htm NOTIFICATION OF LATE FILING

      
     
     
     
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 12b-25
     
    NOTIFICATION OF LATE FILING
     
     
     
    OMB APPROVAL
    OMB Number: 3235-0058
    Expires: April 30, 2025
    Estimated average burden
    hours per response ............ 2.50
     
     
    SEC File Number:
    001-36138
     
    CUSIP Number:
    007624406
     
    (Check one):
     
    ☒ Form 10-K
     
    ☐ Form 20-F
     
    ☐ Form 11-K
     
    ☐ Form 10-Q
     
    ☐ Form 10-D
     
     
    ☐ Form N-CEN
     
    ☐ Form N-CSR
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    For Period Ended:
    December 31, 2023
     
     
    ☐ Transition Report on Form 10-K
     
     
     
     
     
     
    ☐ Transition Report on Form 20-F
     
     
     
     
     
     
    ☐ Transition Report on Form 11-K
     
     
     
     
     
     
    ☐ Transition Report on Form 10-Q
     
     
     
     
     
     
    For the Transition Period Ended:
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Read Instructions (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
     
    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:


    PART I — REGISTRANT INFORMATION
     
    AYALA PHARMACEUTICALS, INC.
    Full Name of Registrant
     
     N/A
    Former Name if Applicable
     
    9 DEER PARK DRIVE, SUITE K-1
    Address of Principal Executive Office (Street and Number)
     
    MONMOUTH JUNCTION, NEW JERSEY 08852
    City, State and Zip Code
     
    PART II — RULES 12b-25(b) AND (c)
     
    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
     
     
    (a)
    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
    ☒
    (b)
    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
    (c)
    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
     

    SEC 1344 (06-19)
    Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

    PART III — NARRATIVE
     
    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
     
    The Company has experienced delays in completing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, within the prescribed time period, as the Company is completing the work of reflecting in the disclosure and financial information set forth in the report the effects of various transactions merger and financing completed during the year. The delay could not be eliminated without unreasonable effort or expense. 
     

    (Attach extra Sheets if Needed)

    PART IV — OTHER INFORMATION
     
    (1)
     
    Name and telephone number of person to contact in regard to this notification
     
     
    Kenneth A. Berlin
     
    (609)
     
    452-9813
     
     
    (Name)
     
    (Area Code)
     
    (Telephone Number)
     
     
     
    (2)
     
    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).
     
     
     
     
     
     
     
     
     
    ☒ Yes   ☐ No
     
     
         
     
     
                 
    (3)
     
    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
     
     
     
     
     
     
     
     
     
    ☒ Yes    ☐ No
     
     
     
     
     
     
     
     
     
    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
     
    The Company estimates revenues and operating loss for the fiscal year ended December 31, 2023 were approximately $13 thousand and $36.2 million, respectively. Revenues and operating loss for the year ended December 31, 2022 were $692 thousand and $37.5 million, respectively.  Our operating results for the year ended December 31, 2023, were impacted by an increase in general and administrative expenses of approximately $2.2 million and a decrease in research and development costs mainly due to the termination of the TENACITY trial and the end of the ACCURACY trial.

    AYALA PHARMACEUTICALS, INC.
    (Name of Registrant as Specified in Charter)
     
    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     
    Date 
    April 1, 2024
     
    By  
    /s/ Roy Golan
     
     
     
     
    Roy Golan, Chief Financial Officer
     
     
     
     
     
     
    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
     
     
    ATTENTION
     
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).


    Get the next $ADXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Israel Biotech Fund I, L.P. bought 1,317,716 shares (SEC Form 4)

    4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

    10/31/23 7:08:02 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    $ADXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

    Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

    1/29/25 9:22:00 AM ET
    $ADXS
    $OSTX
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

    MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Comp

    5/9/24 4:10:00 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

    MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (NASDAQ:IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments. "We are pleased that AL102 will now be advanced by the highly experienced team at Immunome," said Ken Berlin, President and

    3/26/24 8:00:00 AM ET
    $ADXS
    $IMNM
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADXS
    SEC Filings

    View All

    SEC Form 15-12G filed by Advaxis, Inc.

    15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

    5/9/24 4:05:37 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)

    10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

    4/26/24 5:03:01 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)

    8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

    4/19/24 7:50:34 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    $ADXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Israel Biotech Fund I, L.P.

    4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

    3/6/24 7:13:01 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Israel Biotech Fund I, L.P. exercised 27,847,159 shares at a strike of $0.40 and covered exercise/tax liability with 5,294,486 shares (SEC Form 4)

    4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

    2/12/24 2:16:21 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Israel Biotech Fund I, L.P.

    4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

    11/21/23 9:04:41 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    $ADXS
    Leadership Updates

    Live Leadership Updates

    View All

    OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

    Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

    1/29/25 9:22:00 AM ET
    $ADXS
    $OSTX
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

    SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company's Board of Directors as an independent non-executive director, effective on March 31, 2021. Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America's best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biophar

    4/2/21 7:33:00 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    $ADXS
    Financials

    Live finance-specific insights

    View All

    Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

    Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced further results from the Phase 2 (Part A) segment of the RINGSIDE study evaluating AL102 in desmoid tumors. The results were presented in a Poster Discussion Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 3. AL102 is a once-daily, po

    6/5/23 8:00:00 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

    REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the "Company," "New Ayala," "we," "us" or "our") (OTCQX:ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022. Management Commentary "We were pleased to close our previously announced merger in January 2023," said Kenneth A. Berlin, President and Chief Executive Officer of the Company. "Our immediate priorities include executing on Part B of the ongoing registration-enabling RINGSIDE study evaluating AL102 in desmoid tumors. We believe that AL102 has best in class potential and, if approved, m

    2/10/23 7:00:31 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

    Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi

    10/19/22 6:30:00 AM ET
    $ADXS
    $AYLA
    Major Pharmaceuticals
    Health Care
    Specialty Chemicals
    Consumer Discretionary

    $ADXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

    SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

    2/14/24 4:26:22 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Advaxis, Inc. (Amendment)

    SC 13D/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

    2/12/24 11:58:05 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

    SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

    2/12/24 8:27:51 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care